Breaking News

Lilly to Acquire Novartis Animal Health

April 22, 2014

Creates second-largest animal health company

Eli Lilly and Co. has entered an agreement to acquire Novartis Animal Health for approximately $5.4 billion in cash. The acquisition expands Lilly's animal health business, Elanco, and creates the second-largest animal health company in terms of global revenue.
 
Novartis Animal Health has a presence in 40 countries and had approximately $1.1 billion in revenues in 2013. Lilly will acquire its nine manufacturing sites, six dedicated R&D facilities, a global commercial infrastructure with a portfolio of approximately 600 products, a pipeline of more than 40 projects in development, and a team of more than 3,000 employees.
 
The transaction is expected to close by 1Q15, subject to customary closing conditions.
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.